跳转至内容
Merck
CN

27655

Sigma-Aldrich

Colistin sodium methanesulfonate

from Bacillus colistinus

登录查看公司和协议定价

别名:
Colimycin sodium methanesulfonate, Methanesulfonic acid derivative of Polymyxin E, Polymyxin E sodium methanesulfonate
经验公式(希尔记法):
C58H115N16Na5O28S5
CAS号:
分子量:
1759.90
EC 号:
MDL编号:
UNSPSC代码:
51101500
PubChem化学物质编号:
NACRES:
NA.85

生物来源

Bacillus colistinus

质量水平

形式

powder or crystals

灼烧残渣

~20%

缺失

≤5.0% loss on drying

颜色

white to off-white

pH值(酸碱度)

6.5-8.5

抗生素抗菌谱

Gram-negative bacteria

作用机制

cell membrane | interferes

储存温度

2-8°C

SMILES字符串

[Na+].[Na+].[Na+].[Na+].[Na+].CS([O-])(=O)=O.CS([O-])(=O)=O.CS([O-])(=O)=O.CS([O-])(=O)=O.CS([O-])(=O)=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)C(C)O

InChI

1S/C53H100N16O13.5CH4O3S.5Na/c1-9-30(6)12-10-11-13-41(72)60-33(14-20-54)48(77)69-43(32(8)71)53(82)65-36(17-23-57)45(74)64-38-19-25-59-52(81)42(31(7)70)68-49(78)37(18-24-58)62-44(73)34(15-21-55)63-50(79)39(26-28(2)3)67-51(80)40(27-29(4)5)66-46(75)35(16-22-56)61-47(38)76;5*1-5(2,3)4;;;;;/h28-40,42-43,70-71H,9-27,54-58H2,1-8H3,(H,59,81)(H,60,72)(H,61,76)(H,62,73)(H,63,79)(H,64,74)(H,65,82)(H,66,75)(H,67,80)(H,68,78)(H,69,77);5*1H3,(H,2,3,4);;;;;/q;;;;;;5*+1/p-5/t30?,31-,32-,33+,34-,35+,36+,37+,38+,39+,40-,42+,43+;;;;;;;;;;/m1........../s1

InChI key

WSDSONZFNWDYGZ-BKFDUBCBSA-I

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Chemical structure: peptide

应用

Colistin sodium methanesulfate is used to permeabilize bacterial cell membranes and to study mannose-resistant haemagglutination.

生化/生理作用

Colistin sodium methanesulfate is a cyclopolypeptide antibiotic with endotoxin-binding capacity Colistin′s activity stems from the hydrophobic and hydrophillic regions. They solubilze the cytoplasmic membrane which contributes to the bactericidal effect .
Mode of Action: Binds to lipids on the cell cytoplasmic membrane of Gram-negative bacteria and disrupts the cell wall integrity.
Antimicrobial spectrum: Gram-negative bacteria.

包装

1g, 5g

其他说明

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place. Keep in a dry place.

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Matthew E Falagas et al.
Expert review of anti-infective therapy, 6(5), 593-600 (2008-10-14)
Despite the constantly increasing need for new antimicrobial agents, antibiotic drug discovery and development seem to have greatly decelerated in recent years. Presented with the significant problem of advancing antimicrobial resistance, the global scientific community has attempted to find alternative
Roberto Imberti et al.
Chest, 138(6), 1333-1339 (2010-06-19)
Infections caused by multidrug-resistant gram-negative bacteria have caused a resurgence of interest in colistin. To date, information about pharmacokinetics of colistin is very limited in critically ill patients, and no attempts have been made to evaluate its concentration in BAL.
W Couet et al.
Clinical pharmacology and therapeutics, 89(6), 875-879 (2011-05-06)
Colistin pharmacokinetics (PK) was investigated in young healthy volunteers after a 1-h infusion of 80 mg (1 million international units (MIU)) of the prodrug colistin methanesulfonate (CMS). Concentration levels of CMS and colistin were determined in plasma and urine using
S M Garonzik et al.
Antimicrobial agents and chemotherapy, 55(7), 3284-3294 (2011-05-11)
With increasing clinical emergence of multidrug-resistant Gram-negative pathogens and the paucity of new agents to combat these infections, colistin (administered as its inactive prodrug colistin methanesulfonate [CMS]) has reemerged as a treatment option, especially for critically ill patients. There has
Kavi J Littlewood et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 11(5), 419-426 (2012-06-22)
Various inhaled antibiotics are currently used for treating chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients, however their relative efficacies are unclear. We compared the efficacy of the inhaled antibiotics tobramycin (TIP, TIS-T, TIS-B), colistimethate sodium (colistin) and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门